# Edesa Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edesa-biotech

- Industry: Biotechnology
- Headquarters: Markham, Canada
- Website: www.edesabiotech.com
- Total disclosed funding: $5.6M
- Latest round: Series A (Aug 27, 2017)
- Investors on record: 3

## About

Edesa Biotech Inc., located in Ontario, Canada, is a biotechnology company focused on developing monoclonal antibody candidates aimed at treating immuno-inflammatory diseases by modulating immune responses.Founded in 2015, Edesa Biotech Inc. specializes in creating therapeutic solutions for immuno-inflammatory conditions. The company was established following a merger with Stellar Biotechnologies, Inc. in June 2019, which now operates under the Edesa name. Par Nijhawan serves as both the founder and CEO. The company has successfully closed three deals, with the most recent funding round occurring on March 22, 2022, where Edesa Biotech raised CAD 15.00 mn led by Velan Capital, totaling the amount raised to CAD 15.00 mn.Edesa Biotech, Inc. specializes in developing monoclonal antibody candidates designed as host-directed therapeutics for immuno-inflammatory diseases. Their primary focus targets immune dysregulation associated with conditions such as Acute Respiratory Distress Syndrome (ARDS). The company's offerings aim to improve outcomes for critically ill patients by addressing significant health challenges through innovative therapies, serving healthcare providers and research institutions in North America and select international markets.Edesa Biotech generates revenue primarily from partnerships and collaborations related to its therapeutic development programs. These engagements include licensing agreements, research collaborations, and clinical trial partnerships with biopharmaceutical firms and research institutions. Revenue structures involve milestone payments, royalties, and potential product sales tailored to specific agreements as the company advances its drug candidates through clinical studies.Edesa Biotech plans to utilize the recently raised CAD 15.00 mn to advance its pipeline of monoclonal antibody therapeutic candidates and expand into new markets. The company is strategically targeting growth in North America and select international markets by 2023. This expansion is supported by the recent merger with Stellar Biotechnologies, which allows for enhanced operational capabilities and increased market presence. Edesa is also focused on launching new products designed to address unmet medical needs in the immuno-inflammatory space.

## Funding rounds

- Series A, Aug 27, 2017, $5.6M — Inveready Asset Management, Pharmascience, Lumira Ventures

## Investors

- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Series A
- Pharmascience — Series A
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A